share_log

Avalo Therapeutics | SC 13G: Statement of acquisition of beneficial ownership by individuals-Emerald Bioventures, LLC(5.6%),Timothy Opler(5.6%)

Avalo Therapeutics | SC 13G: Statement of acquisition of beneficial ownership by individuals-Emerald Bioventures, LLC(5.6%),Timothy Opler(5.6%)

Avalo Therapeutics | SC 13G：超過5%持股股東披露文件-Emerald Bioventures, LLC(5.6%),Timothy Opler(5.6%)
美股sec公告 ·  04/24 03:00
牛牛AI助理已提取核心訊息
On March 27, 2024, Avalo Therapeutics, Inc. experienced a significant event when Emerald Bioventures, LLC and its managing member Timothy Opler filed a Schedule 13G with the SEC, indicating a 5.6% ownership in Avalo Therapeutics' common stock. This filing was required due to the acquisition of 58,346 shares of Avalo Therapeutics' common stock by Emerald Bioventures, LLC as a result of a merger. The merger involved Avalo Therapeutics, Project Athens Merger Sub, Inc., Second Project Athens Merger Sub, LLC, and AlmataBio, Inc., with the latter two entities merging into wholly owned subsidiaries of Avalo Therapeutics. The shares were acquired on the same day as the merger, and the ownership percentage is based on 1,034,130 shares of common stock outstanding as of that date. The Schedule 13G filing, made under Rule 13d-1(c), indicates that neither Emerald Bioventures, LLC nor Timothy Opler has sole voting or dispositive power over the shares, but they share both voting and dispositive power. The filing asserts that the shares were not acquired for the purpose of changing or influencing the control of Avalo Therapeutics.
On March 27, 2024, Avalo Therapeutics, Inc. experienced a significant event when Emerald Bioventures, LLC and its managing member Timothy Opler filed a Schedule 13G with the SEC, indicating a 5.6% ownership in Avalo Therapeutics' common stock. This filing was required due to the acquisition of 58,346 shares of Avalo Therapeutics' common stock by Emerald Bioventures, LLC as a result of a merger. The merger involved Avalo Therapeutics, Project Athens Merger Sub, Inc., Second Project Athens Merger Sub, LLC, and AlmataBio, Inc., with the latter two entities merging into wholly owned subsidiaries of Avalo Therapeutics. The shares were acquired on the same day as the merger, and the ownership percentage is based on 1,034,130 shares of common stock outstanding as of that date. The Schedule 13G filing, made under Rule 13d-1(c), indicates that neither Emerald Bioventures, LLC nor Timothy Opler has sole voting or dispositive power over the shares, but they share both voting and dispositive power. The filing asserts that the shares were not acquired for the purpose of changing or influencing the control of Avalo Therapeutics.
2024年3月27日，Avalo Therapeutics, Inc.經歷了一起重大事件，當時Emerald Bioventures, LLC及其管理成員蒂莫西·奧勒向美國證券交易委員會提交了附表13G，表示擁有Avalo Therapeutics普通股的5.6％的所有權。之所以需要提交這份文件，是因爲合併後，Emerald Bioventures, LLC收購了Avalo Therapeutics的58,346股普通股。合併涉及Avalo Therapeutics、Project Athens Merger Sub, Inc.、雅典第二項目合併子公司和AlmataBio, Inc.，後兩家實...展開全部
2024年3月27日，Avalo Therapeutics, Inc.經歷了一起重大事件，當時Emerald Bioventures, LLC及其管理成員蒂莫西·奧勒向美國證券交易委員會提交了附表13G，表示擁有Avalo Therapeutics普通股的5.6％的所有權。之所以需要提交這份文件，是因爲合併後，Emerald Bioventures, LLC收購了Avalo Therapeutics的58,346股普通股。合併涉及Avalo Therapeutics、Project Athens Merger Sub, Inc.、雅典第二項目合併子公司和AlmataBio, Inc.，後兩家實體合併爲Avalo Therapeutics的全資子公司。這些股票是在合併當天收購的，所有權百分比基於截至該日已發行的1,034,130股普通股。根據第13d-1（c）條提交的附表13G文件表明，Emerald Bioventures, LLC和Timothy Opler對股票都沒有唯一的投票權或處置權，但它們共享投票權和處置權。該文件稱，收購這些股份不是爲了改變或影響Avalo Therapeutics的控制權。

該公告為獨立文件：

獨立文件1  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。